Rallybio reports Q4 net loss $20.2M, cash $109.9M; workforce cut 45%, Phase 2 RLYB212 on track

Rallybio Corp

Net loss Q4 2023 $20.2M ($0.50/sh); full year loss $74.6M ($1.84/sh).
Cash, equivalents, marketable securities $109.9M at Dec 31, 2023; runway into mid-2026 after 45% workforce reduction.
EMA protocol assistance feedback received for RLYB212; Phase 2 FNAIT study expected to start 2H 2024.
RLYB116 Phase 1 multiple dose showed >93% free C5 reduction; manufacturing enhancements to enable higher doses.
R&D expenses $53.5M (up 31% YoY); G&A $25.4M (down 7% YoY).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 12, 2024, Rallybio Corporation issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-24-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.